AOM names new CEO 

CHARLOTTE, N.C. – AOM Infusion, which provides home-based intravenous immunoglobulin IVIG therapy to patients with more than 80 different chronic conditions, has named Keyur Mehta as CEO. Christopher York will continue in his position as chairman of the company. “Keyur is an experienced specialty infusion executive and we have been impressed by his operational and team building capabilities,” said Petri Lindberg, Principal at Ridgemont Equity Partners, which bought AOM in 2022. “We look forward to continuing to execute AOM’s strategic business plan under Keyur’s leadership.” Mehta brings more than 25 years of experience in health care, primarily within the alternate site infusion and specialty pharma industries. He has been an entrepreneur in the infusion pharmacy and health care consulting spaces and has held executive roles in both public and private companies, including DaVita, Option Care Health, BioScrip and InfuScience. Mehta joined AOM in 2022 as COO and quickly forged a strong partnership with the company’s executive leadership team, as well as the investment team at Ridgemont. Under his leadership, the company has increased its payer network and expanded its therapeutic offerings, while continuing its growth as a leading provider of IVIG infusion therapy. “There is a significant opportunity for AOM to further expand our services into new markets and therapies as patients increasingly opt for at-home and ambulatory treatment options,” he said. “The entire team at AOM has done a remarkable job positioning the company for success. I am energized and excited about our Company’s future and look forward to building on AOM’s exceptional track record.”